Monopar Therapeutics Secures $19.2 Million in Public Offering

Monopar Therapeutics Inc. (Nasdaq: MNPR) has successfully priced a public offering of common stock, raising approximately $19.2 million. The offering, which is expected to close on October 30, 2024, subject to customary closing conditions, saw participation from notable growth and life science investors, including Janus Henderson Investors and RA Capital Management, L.P. Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.

The net proceeds from the offering will be used by Monopar Therapeutics for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital. The securities are being offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-268935), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on December 21, 2022, and declared effective on January 4, 2023.

The successful completion of this public offering signals the market's confidence in Monopar Therapeutics' future prospects. The company's late-stage ALXN-1840 for Wilson disease and radiopharma programs, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1a-stage MNPR-101-Lu, and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, have attracted the attention of growth and life science investors.

Investors in Monopar Therapeutics face potential risks and rewards, given its clinical-stage status and the competitive biotech landscape. The company's near-term ability to raise sufficient funds and its ability to further raise additional funds in the future to support its product candidate programs through completion of clinical trials, regulatory approval, and commercialization are critical factors to consider.

The successful completion of this public offering not only provides Monopar Therapeutics with the necessary funding to support its ongoing operations and growth but also enhances its future funding prospects and valuation. As the company continues to develop innovative treatments for patients with unmet medical needs, investors can expect to see a positive impact on its stock price and market capitalization in the short term.